Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
[1] Schedule 1, after entry for Adalimumab in the form Injection 80 mg in 0.8 mL pre-filled syringe [Maximum Quantity: 3; Number of
Repeats: 0]
insert:
| Adapalene with benzoyl peroxide | Gel 1 mg-25 mg per g, 30 g | 20 | 2 | 3 | |
[2] Schedule 1, entry for Alendronic acid
substitute:
| Alendronic acid | Tablet 70 mg (as alendronate sodium) | 20 | 4 | 5 | |
| | | 20 | 8 | 5 | |
[3] Schedule 1, entry for Allopurinol
substitute:
| Allopurinol | Tablet 100 mg | 20 | 200 | 2 | |
| | | 20 | 400 | 2 | |
| | Tablet 300 mg | 20 | 60 | 2 | |
| | | 20 | 120 | 2 | |
[4] Schedule 1, entry for Amlodipine
substitute:
| Amlodipine | Tablet 5 mg (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[5] Schedule 1, entry for Amlodipine with atorvastatin
substitute:
| Amlodipine with atorvastatin | Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | 20 | 30 | 5 | |
[6] Schedule 1, entry for Amlodipine with valsartan
substitute:
| Amlodipine with valsartan | Tablet 5 mg (as besilate)‑80 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 5 mg (as besilate)‑160 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 5 mg (as besilate)‑320 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 10 mg (as besilate)‑160 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 10 mg (as besilate)‑320 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[7] Schedule 1, entry for Amlodipine with valsartan and hydrochlorothiazide
substitute:
| Amlodipine with valsartan and hydrochlorothiazide | Tablet 5 mg (as besilate)‑160 mg‑12.5 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 5 mg (as besilate)‑160 mg‑25 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 10 mg (as besilate)‑160 mg‑12.5 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 10 mg (as besilate)‑160 mg‑25 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 10 mg (as besilate)‑320 mg‑25 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[8] Schedule 1, entry for Apixaban
substitute:
| Apixaban | Tablet 2.5 mg | 20 | 60 | 0 | |
| | | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
| | Tablet 5 mg | 20 | 28 | 0 | |
| | | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
[9] Schedule 1, entry for Atenolol
substitute:
| Atenolol | Oral solution 50 mg in 10 mL, 300 mL | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
| | Tablet 50 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[10] Schedule 1, entry for Atorvastatin
substitute:
| Atorvastatin | Tablet 10 mg (as calcium) | 20 | 30 | 5 | |
| | | 20 | 30 | 11 | |
| | | 20 | 60 | 5 | |
| | Tablet 20 mg (as calcium) | 20 | 30 | 5 | |
| | | 20 | 30 | 11 | |
| | | 20 | 60 | 5 | |
| | Tablet 40 mg (as calcium) | 20 | 30 | 5 | |
| | | 20 | 30 | 11 | |
| | | 20 | 60 | 5 | |
| | Tablet 80 mg (as calcium) | 20 | 30 | 5 | |
| | | 20 | 30 | 11 | |
| | | 20 | 60 | 5 | |
[11] Schedule 1, after entry for Auranofin in the form Tablet 3 mg
insert:
| Azacitidine | Tablet 200 mg | 20 | 14 | 2 | |
| | Tablet 300 mg | 20 | 14 | 2 | |
| | | 20 | 21 | 1 | |
[12] Schedule 1, entry for Baclofen
substitute:
| Baclofen | Tablet 10 mg | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
| | Tablet 25 mg | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
[13] Schedule 1, entry for Balsalazide
substitute:
| Balsalazide | Capsule containing balsalazide sodium 750 mg | 20 | 280 | 5 | |
| | | 20 | 560 | 5 | |
[14] Schedule 1, entry for Bisoprolol
substitute:
| Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet containing bisoprolol fumarate 5 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet containing bisoprolol fumarate 10 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[15] Schedule 1, after entry for Cabozantinib in the form Tablet 60 mg [Maximum Quantity: 30; Number of Repeats: 5]
insert:
| Calcipotriol with betamethasone | Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g | 20 | 2 | 1 | |
| | Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | 20 | 2 | 1 | |
[16] Schedule 1, entry for Calcitriol
substitute:
| Calcitriol | Capsule 0.25 microgram | 20 | 100 | 3 | |
| | | 20 | 200 | 3 | |
[17] Schedule 1, entry for Calcium
substitute:
| Calcium | Tablet, chewable, 500 mg (as carbonate) | 20 | 480 | 1 | |
| | Tablet 600 mg (as carbonate) | 20 | 240 | 1 | |
| | | 20 | 480 | 1 | |
[18] Schedule 1, entry for Candesartan
substitute:
| Candesartan | Tablet containing candesartan cilexetil 4 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing candesartan cilexetil 8 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing candesartan cilexetil 16 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing candesartan cilexetil 32 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[19] Schedule 1, entry for Candesartan with hydrochlorothiazide
substitute:
| Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[20] Schedule 1, entry for Carvedilol
substitute:
| Carvedilol | Tablet 6.25 mg | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
| | Tablet 12.5 mg | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
| | Tablet 25 mg | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
[21] Schedule 1, after entry for Certolizumab pegol in the form Solution for injection 200 mg in 1 mL pre-filled pen
insert:
| Chlortalidone | Tablet 25 mg | 20 | 200 | 1 | |
[22] Schedule 1, entry for Clonidine
substitute:
| Clonidine | Tablet containing clonidine hydrochloride 100 micrograms | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
| | Tablet containing clonidine hydrochloride 150 micrograms | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
[23] Schedule 1, entry for Clopidogrel
substitute:
| Clopidogrel | Tablet 75 mg (as besilate) | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 75 mg (as hydrogen sulfate) | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[24] Schedule 1, entry for Clopidogrel with aspirin
substitute:
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)‑100 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[25] Schedule 1, entry for Dabigatran etexilate
substitute:
| Dabigatran etexilate | Capsule 75 mg (as mesilate) | 20 | 60 | 0 | |
| | Capsule 110 mg (as mesilate) | 20 | 60 | 0 | |
| | | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
| | Capsule 150 mg (as mesilate) | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
[26] Schedule 1, entry for Enalapril
substitute:
| Enalapril | Tablet containing enalapril maleate 5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing enalapril maleate 10 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing enalapril maleate 20 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[27] Schedule 1, entry for Enalapril with hydrochlorothiazide
substitute:
| Enalapril with hydrochlorothiazide | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[28] Schedule 1, entry for Eplerenone
substitute:
| Eplerenone | Tablet 25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 50 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[29] Schedule 1, entry for Ezetimibe
substitute:
[30] Schedule 1, entry for Ezetimibe and rosuvastatin
substitute:
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
| | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
| | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
| | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
[31] Schedule 1, entry for Ezetimibe with atorvastatin
substitute:
| Ezetimibe with atorvastatin | Tablet 10 mg‑10 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg‑20 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg‑40 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg‑80 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[32] Schedule 1, entry for Ezetimibe with simvastatin
substitute:
| Ezetimibe with simvastatin | Tablet 10 mg‑10 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg‑20 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg‑40 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg‑80 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[33] Schedule 1, entry for Febuxostat
substitute:
| Febuxostat | Tablet 80 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[34] Schedule 1, entry for Felodipine
substitute:
| Felodipine | Tablet 2.5 mg (extended release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 5 mg (extended release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg (extended release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[35] Schedule 1, entry for Fenofibrate
substitute:
| Fenofibrate | Tablet 48 mg | 20 | 60 | 5 | |
| | | 20 | 60 | 11 | |
| | | 20 | 120 | 5 | |
| | Tablet 145 mg | 20 | 30 | 5 | |
| | | 20 | 30 | 11 | |
| | | 20 | 60 | 5 | |
[36] Schedule 1, entry for Fluvastatin
substitute:
| Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | 20 | 28 | 5 | |
| | | 20 | 28 | 11 | |
| | | 20 | 56 | 5 | |
[37] Schedule 1, entry for Furosemide
substitute:
| Furosemide | Oral solution 10 mg per mL, 30 mL | 20 | 2 | 3 | |
| | Tablet 20 mg | 20 | 100 | 1 | |
| | | 20 | 200 | 1 | |
| | Tablet 40 mg | 20 | 100 | 1 | |
| | | 20 | 200 | 1 | |
| | Tablet 500 mg | 20 | 100 | 3 | |
[38] Schedule 1, entry for Gemfibrozil
substitute:
| Gemfibrozil | Tablet 600 mg | 20 | 60 | 5 |
| | | 20 | 60 | 11 |
| | | 20 | 120 | 5 |
[39] Schedule 1, entry for Glyceryl trinitrate
substitute:
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | 20 | 2 | 5 | |
| | Transdermal patch 18 mg | 20 | 30 | 5 | |
| | Transdermal patch 25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Transdermal patch 36 mg | 20 | 30 | 5 | |
| | Transdermal patch 50 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Transdermal patch 54 mg | 20 | 30 | 5 | |
[40] Schedule 1, entry for Hydrochlorothiazide
substitute:
| Hydrochlorothiazide | Tablet 25 mg | 20 | 100 | 1 | |
| | | 20 | 200 | 1 | |
[41] Schedule 1, entry for Hydrochlorothiazide with amiloride
substitute:
| Hydrochlorothiazide with amiloride | Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg | 20 | 100 | 1 | |
| | | 20 | 200 | 1 | |
[42] Schedule 1, entry for Indapamide
substitute:
| Indapamide | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 20 | 90 | 1 | |
| | | 20 | 180 | 1 | |
| | Tablet containing indapamide hemihydrate 2.5 mg | 20 | 90 | 1 | |
| | | 20 | 180 | 1 | |
[43] Schedule 1, entry for Irbesartan
substitute:
| Irbesartan | Tablet 75 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 150 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 300 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[44] Schedule 1, entry for Irbesartan with hydrochlorothiazide
substitute:
| Irbesartan with hydrochlorothiazide | Tablet 150 mg‑12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 300 mg‑12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 300 mg‑25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[45] Schedule 1, after entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 60; Number of Repeats: 5]
insert:
| Isosorbide dinitrate | Tablet 5 mg (sublingual) | 20 | 400 | 2 | |
[46] Schedule 1, entry for Isosorbide mononitrate
substitute:
| Isosorbide mononitrate | Tablet 60 mg (sustained release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 120 mg (sustained release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[47] Schedule 1, entry for Lercanidipine
substitute:
| Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet containing lercanidipine hydrochloride 20 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[48] Schedule 1, entry for Lercanidipine with enalapril
substitute:
| Lercanidipine with enalapril | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[49] Schedule 1, entry for Lisinopril
substitute:
| Lisinopril | Tablet 5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 10 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 20 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[50] Schedule 1, omit entry for Losartan
[51] Schedule 1, entry for Mesalazine
substitute:
| Mesalazine | Sachet containing granules, 500 mg per sachet | 20 | 200 | 5 | |
| | | 20 | 400 | 5 | |
| | Sachet containing granules, 1 g per sachet | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
| | Sachet containing granules, 1.5 g per sachet | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
| | Sachet containing granules, 3 g per sachet | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Sachet containing prolonged release granules, 1 g per sachet | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
| | Sachet containing prolonged release granules, 2 g per sachet | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
| | Sachet containing prolonged release granules, 4 g per sachet | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 250 mg (enteric coated) | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
| | Tablet 500 mg (enteric coated) | 20 | 200 | 5 | |
| | | 20 | 400 | 5 | |
| | Tablet 500 mg (prolonged release) | 20 | 200 | 5 | |
| | | 20 | 400 | 5 | |
| | Tablet 800 mg (enteric coated) | 20 | 90 | 5 | |
| | | 20 | 180 | 5 | |
| | Tablet 1 g (enteric coated) | 20 | 120 | 5 | |
| | | 20 | 240 | 5 | |
| | Tablet 1 g (prolonged release) | 20 | 120 | 5 | |
| | | 20 | 240 | 5 | |
| | Tablet 1.2 g (prolonged release) | 20 | 120 | 5 | |
| | | 20 | 240 | 5 | |
| | Tablet 1.6 g (enteric coated) | 20 | 120 | 4 | |
| | | 20 | 240 | 4 | |
[52] Schedule 1, entry for Metoprolol
substitute:
| Metoprolol | Tablet containing metoprolol tartrate 50 mg | 20 | 100 | 5 | |
| | | 20 | 200 | 5 | |
| | Tablet containing metoprolol tartrate 100 mg | 20 | 60 | 5 | |
| | | 20 | 120 | 5 | |
[53] Schedule 1, entry for Metoprolol succinate
substitute:
| Metoprolol succinate | Tablet 47.5 mg (controlled release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 95 mg (controlled release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 190 mg (controlled release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[54] Schedule 1, entry for Moxonidine
substitute:
| Moxonidine | Tablet 200 micrograms | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 400 micrograms | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[55] Schedule 1, entry for Nebivolol
substitute:
| Nebivolol | Tablet 1.25 mg (as hydrochloride) | 20 | 56 | 5 | |
| | | 20 | 112 | 5 | |
| | Tablet 5 mg (as hydrochloride) | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
| | Tablet 10 mg (as hydrochloride) | 20 | 28 | 5 | |
| | | 20 | 56 | 5 | |
[56] Schedule 1, entry for Nicorandil
substitute:
| Nicorandil | Tablets 10 mg, 60 | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
| | Tablets 20 mg, 60 | 20 | 1 | 5 | |
| | | 20 | 2 | 5 | |
[57] Schedule 1, entry for Nifedipine
substitute:
| Nifedipine | Tablet 30 mg (controlled release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet 60 mg (controlled release) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[58] Schedule 1, omit entry for Norethisterone with mestranol
[59] Schedule 1, entry for Olmesartan
substitute:
| Olmesartan | Tablet containing olmesartan medoxomil 20 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[60] Schedule 1, entry for Olmesartan with amlodipine
substitute:
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | 20 | 30 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | 20 | 30 | 5 | |
[61] Schedule 1, entry for Olmesartan with amlodipine and hydrochlorothiazide
substitute:
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | 20 | 30 | 5 | |
[62] Schedule 1, entry for Olmesartan with hydrochlorothiazide
substitute:
| Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[63] Schedule 1, entry for Ozanimod
substitute:
| Ozanimod | Capsule 920 micrograms | 20 | 28 | 3 | |
| | | 20 | 28 | 5 | |
| | Pack containing 4 capsules 230 micrograms and 3 capsules
460 micrograms | 20 | 1 | 0 | |
[64] Schedule 1, after entry for Palbociclib in the form Tablet 125 mg
insert:
| Pancreatic extract | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | 20 | 1000 | 10 | |
| | Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | 20 | 400 | 10 | |
| | Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity | 20 | 400 | 10 | |
| | Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g | 20 | 6 | 10 | |
[65] Schedule 1, after entry for Paroxetine
insert:
| Patiromer | Powder for oral suspension 8.4 g | 20 | 30 | 5 | |
| | Powder for oral suspension 16.8 g | 20 | 30 | 5 | |
[66] Schedule 1, after entry for Pazopanib in the form Tablet 400 mg (as hydrochloride) [Maximum Quantity: 60; Number of Repeats: 5]
insert:
| Penicillamine | Tablet 125 mg | 20 | 200 | 1 | |
| | Tablet 250 mg | 20 | 200 | 1 | |
[67] Schedule 1, entry for Perindopril
substitute:
| Perindopril | Tablet containing perindopril arginine 2.5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril arginine 5 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril arginine 10 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril erbumine 2 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril erbumine 4 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril erbumine 8 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[68] Schedule 1, entry for Perindopril with amlodipine
substitute:
| Perindopril with amlodipine | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[69] Schedule 1, entry for Perindopril with indapamide
substitute:
| Perindopril with indapamide | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
| | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | 20 | 30 | 5 | |
| | | 20 | 60 | 5 | |
[70] Schedule 1, entry for Potassium chloride
substitute:
| Potassium chloride | Tablet 600 mg (sustained release) | 20 | 200 | 1 | |
| | | 20 | 400 | 1 | |
[71] Schedule 1, entry for Potassium chloride with potassium bicarbonate
substitute:
| Potassium chloride with potassium bicarbonate | Tablet, effervescent, 14 mmol potassium and 8 mmol chloride | 20 | 60 | 1 | |
| | | 20 | 120 | 1 | |
[72] Schedule 1, entry for Pravastatin
substitute:
| Pravastatin | Tablet containing pravastatin sodium 10 mg | 20 | 30 | |